The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study
Henrik Ekberg(Malmö University), Pierre Daloze(Hôpital Notre-Dame), Flavio Vincenti(University of California, San Francisco), Thomas C. Pearson(Emory Healthcare), Hélio Tedesco‐Silva(Hospital do Rim e Hipertensão), Richard D. Mamelok(Johnson & Johnson (United States))
Cited by 67
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566